Hepatocellular carcinoma with complete response to the immunotherapy:the oncologist’s dilemma

作     者：Mansour Al-Moundhri Antonio Cubisino Fabrizio Panaro 

作者机构：Medical Oncology DepartmentSultan Qaboos Comprehensive Cancer CenterSultan Qaboos UniversityMuscatOman Department of SurgeryUniversity of Illinois at ChicagoChicagoILUSA Department of SurgeryMontpellier University HospitalMontpellierFrance Surgical Oncology DepartmentSultan Qaboos Comprehensive Cancer CenterSultan Qaboos UniversityMuscatOman 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2022年第11卷第1期

页      面：119-122页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：cancer immunotherapy clinical 

摘      要：Hepatocellular carcinoma(HCC)is the seventh most common cancer and the fourth leading cause of cancer-related death worldwide(1).During the last decade,many efforts have been made to improve patient survival by conducting clinical trials investigating local and systemic treatment options for patients with unresectable ***,despite significant research efforts,only few treatment approaches have been validated for HCC.